Drug Profile


Alternative Names: [14C]E2609; E-2609

Latest Information Update: 20 Dec 2016

Price : $50

At a glance

  • Originator Eisai Inc
  • Developer Eisai Inc; GE Healthcare
  • Class Antidementias; Small molecules
  • Mechanism of Action BACE1 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    Alzheimer's disease
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 12 Dec 2016 Efficacy data from a phase I trial in Healthy volunteers presented at the 9th Clinical Trials on Alzheimer's Disease Meeting (CTAD-2016)
  • 17 Nov 2016 Elenbecestat receives Fast Track designation for Alzheimer's disease [PO,Tablet] (Early-stage disease) in USA
  • 31 Oct 2016 Phase-III clinical trials in Alzheimer's disease (Early-stage disease) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top